Stock Analysis

3 High Growth Swedish Tech Stocks To Watch

OM:BIOA B
Source: Shutterstock

As global markets grapple with geopolitical tensions and economic uncertainties, European stocks have faced downward pressure, with the pan-European STOXX Europe 600 Index ending lower due to escalating conflicts in the Middle East. In this environment of caution and volatility, identifying promising high-growth tech stocks in Sweden requires a focus on companies that demonstrate resilience and innovation amidst broader market challenges.

Top 10 High Growth Tech Companies In Sweden

NameRevenue GrowthEarnings GrowthGrowth Rating
Truecaller20.32%21.61%★★★★★★
Xbrane Biopharma53.90%118.02%★★★★★★
Bonesupport Holding33.76%31.20%★★★★★★
Scandion Oncology40.71%75.34%★★★★★★
Hemnet Group20.12%25.41%★★★★★★
Skolon32.63%122.14%★★★★★★
BioArctic42.38%98.40%★★★★★★
Biovica International81.67%78.55%★★★★★★
KebNi34.75%86.11%★★★★★★
Yubico20.52%42.35%★★★★★★

Click here to see the full list of 80 stocks from our Swedish High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

BioArctic (OM:BIOA B)

Simply Wall St Growth Rating: ★★★★★★

Overview: BioArctic AB (publ) focuses on developing biological drugs for central nervous system disorders in Sweden, with a market cap of SEK14.15 billion.

Operations: The company generates revenue primarily from its biotechnology segment, which reported SEK299.35 million. The focus is on developing biological drugs targeting central nervous system disorders.

BioArctic stands out in the Swedish tech landscape, not just for its impressive forecasted revenue growth of 42.4% annually but also for its potential to pivot into profitability with an anticipated earnings surge of 98.4% per year. Recent strides in R&D have bolstered its portfolio, notably with the development of exidavnemab for Parkinson’s disease and the significant progress of Leqembi for Alzheimer's, approved across multiple regions including the UAE and Hong Kong. This focus on high-impact neurological treatments underscores BioArctic's commitment to addressing critical health issues through innovation, setting a robust foundation for future growth despite current unprofitability and market volatility.

OM:BIOA B Revenue and Expenses Breakdown as at Oct 2024
OM:BIOA B Revenue and Expenses Breakdown as at Oct 2024

Embracer Group (OM:EMBRAC B)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Embracer Group AB (publ) is a global company that develops and publishes games across various platforms, including PC, console, mobile, VR, and board games, with a market capitalization of approximately SEK39.15 billion.

Operations: The company generates revenue primarily from PC/console games, tabletop games, mobile games, and entertainment & services. The largest revenue segment is tabletop games at SEK14.65 billion, followed by PC/console games at SEK13.10 billion.

Embracer Group, navigating through a challenging tech landscape, has shown resilience with its strategic board reshuffles and securing a new EUR 600 million credit facility to bolster financial flexibility. Despite a recent downturn in quarterly revenue—from SEK 10,540 million to SEK 8,050 million—and transitioning from net income to a loss of SEK 2,183 million, the company is poised for recovery. R&D investments remain pivotal as Embracer aims for profitability with forecasted earnings growth of an impressive 129.9% annually and modest revenue growth at 3.2% per year—outpacing the Swedish market's average. These efforts reflect Embracer's commitment to innovation and sector leadership in an evolving entertainment industry.

OM:EMBRAC B Revenue and Expenses Breakdown as at Oct 2024
OM:EMBRAC B Revenue and Expenses Breakdown as at Oct 2024

Yubico (OM:YUBICO)

Simply Wall St Growth Rating: ★★★★★★

Overview: Yubico AB offers authentication solutions for computers, networks, and online services, with a market cap of SEK23.51 billion.

Operations: The company generates revenue primarily from its Security Software & Services segment, amounting to SEK2.09 billion.

Yubico, amid a rapidly evolving cybersecurity landscape, continues to enhance its market position through strategic partnerships and innovative product offerings. Recently, the company reported a robust 21.2% year-over-year revenue growth, reaching SEK 1.113 billion in the first half of 2024, underpinned by significant contracts such as with PKO Bank Polski for high-security authentication solutions. This aligns with an aggressive R&D strategy where expenses surged by 20.5%, reflecting Yubico's commitment to advancing secure digital access technologies. Moreover, anticipated earnings growth stands at an impressive 42.3% annually over the next three years, showcasing potential despite a more volatile share price recently. These figures underscore Yubico's proactive approach in a sector where enhanced security measures are increasingly critical.

OM:YUBICO Revenue and Expenses Breakdown as at Oct 2024
OM:YUBICO Revenue and Expenses Breakdown as at Oct 2024

Next Steps

  • Navigate through the entire inventory of 80 Swedish High Growth Tech and AI Stocks here.
  • Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
  • Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if BioArctic might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com